Plain-English translation of NCT04178174 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether a shorter course of radiation therapy using advanced precision targeting—combined with chemotherapy—works as well as the standard 7-week radiation treatment for people with HPV-related oropharynx cancer. The new approach uses stereotactic ablative radiotherapy (SABR), a technique that delivers very focused, high-dose radiation to tumors while sparing nearby healthy tissue. The goal is to shrink treatment time while reducing side effects and maintaining cure rates.
Current radiation therapy for this type of throat cancer takes 7 weeks and causes significant side effects that hurt quality of life. Recent research shows that HPV-related throat cancers respond well to treatment and may not need the full standard dose, creating an opportunity to test whether a shorter, more precise approach could be equally effective while causing fewer long-term problems.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will be randomly assigned to receive either the new short-course treatment or the standard 7-week treatment. The new approach involves a 2-day intensive radiation boost followed by 4 weeks of lower-dose radiation with chemotherapy infusions. The standard arm involves 7 weeks of daily radiation with chemotherapy given every 3 weeks. Either way, you will need multiple clinic visits for imaging, treatment planning, and follow-up care to monitor how well the treatment is working and manage any side effects.
AI-generated summary from trial data · Jul 4, 2026 · Not medical advice
Canada